Amarin Corporation Plc Sponsored ADR Stock

$0.40

4.73% yesterday

Nasdaq, Apr 04, 10:03 pm CET

ISIN

US0231112063

Symbol

AMRN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Amarin Corporation Plc Sponsored ADR Stock price

$0.40

-4.40 91.61% 5Y

Nasdaq, Closing price Fri, Apr 04 2025

-0.02 4.73%

ISIN

US0231112063

Symbol

AMRN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$165.70m
Enterprise Value	$-121.10m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	3.90
EV/Sales (TTM) EV/Sales	-0.53
P/S ratio (TTM) P/S ratio	0.73
P/B ratio (TTM) P/B ratio	0.34
Revenue growth (TTM) Revenue growth	-25.86%
Revenue (TTM) Revenue	$228.51m
EBIT (operating result TTM) EBIT	$-55.43m
Free Cash Flow (TTM) Free Cash Flow	$-31.03m
Cash position	$294.52m
EPS (TTM) EPS	$-0.20
P/E forward	negative
P/S forward	0.89
EV/Sales forward	negative
Short interest	2.65%

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Get Started for Free Today

Amarin Corporation Plc Sponsored ADR Stock Analysis

Unlock Scores for Free

??

2 Analysts have issued a Amarin Corporation Plc Sponsored ADR forecast:

1x Hold

50%

1x Sell

50%

More details on Analyst Estimates Including Price Targets

2 Analysts have issued a Amarin Corporation Plc Sponsored ADR forecast:

Hold

50%

Sell

50%

Analyst Estimates with Stock Price Targets

Financial data from Amarin Corporation Plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	229 229	26% 26% 100%
- Direct Costs	114 114	21% 21% 50%
Gross Profit	115 115	30% 30% 50%
- Selling and Administrative Expenses	149 149	24% 24% 65%
- Research and Development Expense	18 18	8% 8% 8%
EBITDA	-52 -52	3% 3% -23%
- Depreciation and Amortization	3.01 3.01	1% 1% 1%
EBIT (Operating Income) EBIT	-55 -55	2% 2% -24%
Net Profit	-82 -82	38% 38% -36%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Amarin Corporation Plc Sponsored ADR Stock News

Neutral

Business Wire

●

17 days ago

Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok, the Managing Director of JEC Capital Partners (together with certain of their affiliates, the “Concerned Shareholder Group” or “we”), who collectively own approximately 15 million shares of Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”), today issued the following open letter to the Company's Board of Directors. *...

Neutral

GlobeNewsWire

●

17 days ago

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

DUBLIN and BRIDGEWATER, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional in vitro mechanistic data with eicosapentaenoic acid (EPA) will be presented at the American College of Cardiology's Annual Scientific Session & Expo, March 29-31, 2025, in Chicago, IL.

Neutral

Seeking Alpha

●

24 days ago

Amarin Corporation plc (AMRN) Q4 2024 Earnings Call Transcript

Amarin Corporation plc (NASDAQ:AMRN ) Q4 2024 Earnings Conference Call March 12, 2025 8:00 AM ET Company Participants Mark Marmur - Vice President of Corporate Communications and Investor Relations Aaron Berg - President and Chief Executive Officer Peter Fishman - Vice President and Global Controller Steven Ketchum - Executive Vice President, President of R&D and Chief Scientific Officer Confer...

More Amarin Corporation Plc Sponsored ADR News

Company Profile

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Head office	United Kingdom
CEO	Aaron Berg
Employees	275
Founded	1989
Website	www.amarincorp.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now